Outcomes associated with empiric cefepime for bloodstream infections caused by ceftriaxone-resistant, cefepime-susceptible Escherichia coli and Klebsiella pneumoniae-Reference-Cited by-同舟云学术

Outcomes associated with empiric cefepime for bloodstream infections caused by ceftriaxone-resistant, cefepime-susceptible Escherichia coli and Klebsiella pneumoniae

Published:2023-05 Issue:5 Volume:61 Page:106762
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Frescas Brian E.^ORCID,McCoy Christopher M.^ORCID,Kirby James^ORCID,Bowden Robert,Mercuro Nicholas J.^ORCID

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine

Reference26 articles.

1. Mortality risk of bloodstream infection caused by either Escherichia coli or Klebsiella pneumoniae producing extended-spectrum β-lactamase: a prospective cohort study;Sianipar;BMC Res Notes,2019

2. Antibiotic Resistance Threats in the United States,2019

3. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia;Tamma;Clin Infect Dis,2015

4. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E. coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial;Harris;JAMA,2018

5. Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae;Ofer-Friedman;Infect Control Hosp Epidemiol,2015

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Carbapenem use in extended-spectrum cephalosporin-resistant Enterobacterales infections in US hospitals and influence of IDSA guidance: a retrospective cohort study;The Lancet Infectious Diseases;2024-08

2. Is Carbapenem Therapy Necessary for the Treatment of Non-CTX-M Extended-Spectrum β-Lactamase-Producing Enterobacterales Bloodstream Infections?;Clinical Infectious Diseases;2023-11-16

3. Should cefepime be used for any bloodstream infections caused by ceftriaxone-resistant, cefepime-susceptible Enterobacterales?;International Journal of Antimicrobial Agents;2023-09

4. The Impact of ESBLs-Positive Escherichia coli’s Resistance to Cefepime and Its Guidance for Clinical Treatment;Infection and Drug Resistance;2023-09

5. Risk Factors for Bloodstream Infections Due to ESBL-Producing Escherichia coli, Klebsiella spp., and Proteus mirabilis;Pharmacy;2023-04-13